These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 22004687)

  • 1. Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite.
    Boulenc X; Djebli N; Shi J; Perrin L; Brian W; Van Horn R; Hurbin F
    Drug Metab Dispos; 2012 Jan; 40(1):187-97. PubMed ID: 22004687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.
    Djebli N; Fabre D; Boulenc X; Fabre G; Sultan E; Hurbin F
    Drug Metab Dispos; 2015 Apr; 43(4):510-22. PubMed ID: 25609219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
    Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
    Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of omeprazole on platelet inhibition of clopidogrel in various CYP2C19 mutant alleles.
    Liu Q; Dang DS; Chen YF; Yan M; Shi GB; Zhao QC
    Genet Test Mol Biomarkers; 2012 Nov; 16(11):1293-7. PubMed ID: 23046071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.
    Simon T; Bhatt DL; Bergougnan L; Farenc C; Pearson K; Perrin L; Vicaut E; Lacreta F; Hurbin F; Dubar M
    Clin Pharmacol Ther; 2011 Aug; 90(2):287-95. PubMed ID: 21716274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of proton pump inhibitor omeprazole on the antiplatelet effect of clopidogrel in individuals with various CYP2C19*2 genotypes].
    Lu FM; Tong ZL; Mao YM; Wu DY; Xu J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Aug; 29(4):478-81. PubMed ID: 22875511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel.
    Nishiya Y; Hagihara K; Kurihara A; Okudaira N; Farid NA; Okazaki O; Ikeda T
    Xenobiotica; 2009 Nov; 39(11):836-43. PubMed ID: 19845434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.
    Yu KS; Yim DS; Cho JY; Park SS; Park JY; Lee KH; Jang IJ; Yi SY; Bae KS; Shin SG
    Clin Pharmacol Ther; 2001 Apr; 69(4):266-73. PubMed ID: 11309556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms.
    Chen BL; Chen Y; Tu JH; Li YL; Zhang W; Li Q; Fan L; Tan ZR; Hu DL; Wang D; Wang LS; Ouyang DS; Zhou HH
    J Clin Pharmacol; 2009 May; 49(5):574-81. PubMed ID: 19398604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.
    Tiroch KA; Sibbing D; Koch W; Roosen-Runge T; Mehilli J; Schömig A; Kastrati A
    Am Heart J; 2010 Sep; 160(3):506-12. PubMed ID: 20826260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of genetic and non-genetic factors on the plasma concentrations of the clopidogrel metabolite (SR26334) among Chinese patients.
    Zhou H; Meng S; Zhao J; Dong J; Xu A; Wang F; Guzalnur T; Xin J; Zhang J; Wang J; Cai W
    Clin Chim Acta; 2013 Feb; 416():50-3. PubMed ID: 23201489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease.
    Ohnishi A; Murakami S; Akizuki S; Mochizuki J; Echizen H; Takagi I
    J Clin Pharmacol; 2005 Nov; 45(11):1221-9. PubMed ID: 16239354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C19 genetic polymorphism, rabeprazole and esomeprazole have no effect on the antiplatelet action of clopidogrel.
    El-Halabi MM; Zgheib N; Mansour NM; Malli A; Ghaith OA; Mahfouz R; Alam S; Sharara AI
    J Cardiovasc Pharmacol; 2013 Jul; 62(1):41-9. PubMed ID: 23474843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
    Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
    Hulot JS; Collet JP; Cayla G; Silvain J; Allanic F; Bellemain-Appaix A; Scott SA; Montalescot G
    Circ Cardiovasc Interv; 2011 Oct; 4(5):422-8. PubMed ID: 21972404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine.
    Grün B; Merkel U; Riedel KD; Weiss J; Mikus G
    Br J Clin Pharmacol; 2012 Nov; 74(5):854-63. PubMed ID: 22381043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
    Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
    J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis.
    Zendehdel N; Biramijamal F; Hossein-Nezhad A; Zendehdel N; Sarie H; Doughaiemoghaddam M; Pourshams A
    Arch Iran Med; 2010 Sep; 13(5):406-12. PubMed ID: 20804307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Collet JP; Hulot JS; Pena A; Villard E; Esteve JB; Silvain J; Payot L; Brugier D; Cayla G; Beygui F; Bensimon G; Funck-Brentano C; Montalescot G
    Lancet; 2009 Jan; 373(9660):309-17. PubMed ID: 19108880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P-450 polymorphisms and response to clopidogrel.
    Taubert D; Bouman HJ; van Werkum JW
    N Engl J Med; 2009 May; 360(21):2249-50; author reply 2251. PubMed ID: 19458375
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.